Editing Castrate-Resistant Prostate Cancer (section)

====== Rucaparib ======
* '''Indications'''
** '''FDA-approved for patients with BRCA 1/2 associated with mCRPC who have been treated with an ARAT and a taxane-based chemotherapy'''
* '''TRITON-2'''
** Phase II trial
** Population: 115 patients with a ''BRCA'' alteration, who progressed after one to two lines of next-generation androgen receptor-directed therapy and one taxane-based chemotherapy for mCRPC, with or without measurable disease
** Abida, Wassim, et al."Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration." ''Journal of Clinical Oncology'' 38.32 (2020): 3763.